JP2020501512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501512A5 JP2020501512A5 JP2019515810A JP2019515810A JP2020501512A5 JP 2020501512 A5 JP2020501512 A5 JP 2020501512A5 JP 2019515810 A JP2019515810 A JP 2019515810A JP 2019515810 A JP2019515810 A JP 2019515810A JP 2020501512 A5 JP2020501512 A5 JP 2020501512A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- item
- hla
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 126
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 58
- 150000007523 nucleic acids Chemical group 0.000 claims description 57
- 229920001184 polypeptide Polymers 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 210000002865 immune cell Anatomy 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 230000011664 signaling Effects 0.000 claims description 23
- 108091035707 Consensus sequence Proteins 0.000 claims description 21
- 102100027207 CD27 antigen Human genes 0.000 claims description 16
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 16
- 230000000139 costimulatory effect Effects 0.000 claims description 16
- 108091033409 CRISPR Proteins 0.000 claims description 13
- 238000010354 CRISPR gene editing Methods 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 10
- -1 4-IBB (CD137) Proteins 0.000 claims description 8
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 8
- 101710145634 Antigen 1 Proteins 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 8
- 108091008874 T cell receptors Proteins 0.000 claims description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 8
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 8
- 230000009368 gene silencing by RNA Effects 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 7
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 108091008039 hormone receptors Proteins 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 4
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 6
- 108010024164 HLA-G Antigens Proteins 0.000 description 6
- 102000014650 luteinizing hormone receptor activity proteins Human genes 0.000 description 5
- 108040006978 luteinizing hormone receptor activity proteins Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 241000283086 Equidae Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399244P | 2016-09-23 | 2016-09-23 | |
| US62/399,244 | 2016-09-23 | ||
| PCT/US2017/052974 WO2018057904A1 (en) | 2016-09-23 | 2017-09-22 | Chimeric antigen receptors and compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020501512A JP2020501512A (ja) | 2020-01-23 |
| JP2020501512A5 true JP2020501512A5 (enExample) | 2020-11-12 |
Family
ID=61689763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515810A Pending JP2020501512A (ja) | 2016-09-23 | 2017-09-22 | キメラ抗原受容体およびその組成物ならびにそれらの使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200016201A1 (enExample) |
| EP (1) | EP3515493A4 (enExample) |
| JP (1) | JP2020501512A (enExample) |
| CN (1) | CN110225766A (enExample) |
| AU (1) | AU2017330423A1 (enExample) |
| CA (1) | CA3037528A1 (enExample) |
| IL (1) | IL265438B2 (enExample) |
| WO (1) | WO2018057904A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
| KR102664453B1 (ko) * | 2017-02-21 | 2024-05-10 | 주식회사 유틸렉스 | Hla-dr car-t 조성물 및 그를 제조하고 사용하는 방법 |
| CN109111525B (zh) * | 2018-05-24 | 2021-10-29 | 卢英 | 一种hla-g嵌合抗原受体、编码序列和表达载体以及应用 |
| MX2021001672A (es) | 2018-08-10 | 2021-07-15 | Eutilex Co Ltd | Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car. |
| MX2021002316A (es) | 2018-08-31 | 2021-07-15 | Invectys SA | Receptores de antígeno quimérico frente a múltiples isoformas de hla-g. |
| CN110903399B (zh) * | 2018-09-17 | 2022-02-01 | 台湾中国医药大学附设医院 | 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物 |
| TWI694083B (zh) * | 2018-09-17 | 2020-05-21 | 中國醫藥大學附設醫院 | 嵌合抗原受體、核酸、嵌合抗原受體表達質體、表達嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| CN111718957A (zh) * | 2019-03-22 | 2020-09-29 | 南京安锐生物科技有限公司 | 一种嵌合抗原受体重组腺相关病毒颗粒及其应用 |
| TWI717880B (zh) * | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550155C (en) * | 2003-12-15 | 2015-03-17 | Dendreon Corporation | Hla-dr-specific antibodies, compositions and methods |
| GB0408449D0 (en) * | 2004-04-15 | 2004-05-19 | Banerjee Subhasis | Diagnostic and therapeutic applications of soluble lhcge protein |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| US20140348744A1 (en) * | 2013-05-24 | 2014-11-27 | Jacek K. Pinski | Compositions and methods for regulating cancer-related signaling pathways |
| CA2927543C (en) * | 2013-10-15 | 2021-07-20 | The California Institute For Biomedical Research | Peptidic chimeric antigen receptor t cell switches and uses thereof |
| US11186824B2 (en) * | 2015-03-11 | 2021-11-30 | Cellectis | Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients |
| EP3273994B1 (en) * | 2015-03-27 | 2021-12-01 | University of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| CN105949316B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗EGFRvIII嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
-
2017
- 2017-09-22 CA CA3037528A patent/CA3037528A1/en not_active Abandoned
- 2017-09-22 JP JP2019515810A patent/JP2020501512A/ja active Pending
- 2017-09-22 US US16/335,570 patent/US20200016201A1/en not_active Abandoned
- 2017-09-22 WO PCT/US2017/052974 patent/WO2018057904A1/en not_active Ceased
- 2017-09-22 AU AU2017330423A patent/AU2017330423A1/en not_active Abandoned
- 2017-09-22 IL IL265438A patent/IL265438B2/en unknown
- 2017-09-22 CN CN201780071631.4A patent/CN110225766A/zh active Pending
- 2017-09-22 EP EP17853995.3A patent/EP3515493A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501512A5 (enExample) | ||
| JP2025032089A (ja) | 腫瘍微小環境を標的とするキメラ抗原受容体 | |
| JP2024062986A (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| RU2021121771A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| JP2018518939A5 (enExample) | ||
| KR20230167766A (ko) | Cd19에 특이적인 항체 및 키메라 항원 수용체 | |
| KR20230130148A (ko) | Ｃｄ20 결합 분자 및 그의 용도 | |
| JP2020512973A5 (enExample) | ||
| JP2018518152A5 (enExample) | ||
| US20190092876A1 (en) | T-cell receptor mimic (tcrm) antibodies | |
| JP2018518151A5 (enExample) | ||
| JP2021505663A5 (enExample) | ||
| CN111848809A (zh) | 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途 | |
| JP7319250B2 (ja) | Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用 | |
| CN114206919A (zh) | 靶向taci的抗体和嵌合抗原受体 | |
| JP2024501888A (ja) | Ｂｃｍａに特異的に結合する抗体およびその使用 | |
| KR20210143096A (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
| US20240400705A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| JP2024012258A (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| CN113423720A (zh) | CAR文库和scFv的制造方法 | |
| KR20230072536A (ko) | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 | |
| JP2021181453A (ja) | 抗イヌｃｄ２０モノクローナル抗体 |